RFP
FHTX icon

Root Financial Partners’s Foghorn Therapeutics FHTX Stock Holding History

Root Financial Partners’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-28
Closed -$134 – 1368
2026
Q1 		$134 Buy
+28
New +$154 ﹤0.01% 3230

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
EC
Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Root Financial Partners's FHTX Position: Q2 2026 in Review

Root Financial Partners sold out of Foghorn Therapeutics (FHTX) in Q2 2026, closing a stake of 28 shares — an estimated $134 sold.

Root Financial Partners first reported a position in FHTX in Q1 2026 and held it in 1 quarter. The position peaked at $134 in Q1 2026. 102 funds tracked by Wall St. Rank hold FHTX as of Q2 2026.

  • Root Financial Partners reported no remaining Foghorn Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Root Financial Partners sold 28 Foghorn Therapeutics shares in Q2 2026, an estimated $134.
  • Root Financial Partners first reported a position in Foghorn Therapeutics in Q1 2026 and held it in 1 quarter.
  • Root Financial Partners's Foghorn Therapeutics position peaked at $134 in Q1 2026.
  • 102 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2026.

Based on Root Financial Partners's 13F filing for Q2 2026, filed 29 Jul 2026.